Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Aries Wealth Management has tiptoed into biotech by acquiring 605 shares of Vertex Pharmaceuticals, valued around $293,000. Other hedge funds also took notice, adjusting their positions during the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CCM Investment Advisers gave Vertex Pharmaceuticals a vitamin shot by upping its stake 24.1% in Q1. They purchased an ...

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1% at $455.45. This change was narrower than the S&P 500's daily loss of 1.13%. Elsewhere, the Dow lost 1.79%, while the tech-heavy ...

The stock's fall snapped a three-day winning streak.

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.